Related Experiment Video
Updated: Jun 14, 2025
Creation of Reversible Cholestatic Rat Model
Published on: May 21, 2011
Randomised post-test-only study of glutathione and ursodeoxycholic acid combination therapy on liver function in
A A Prasetyo1, B Rachmawati2, I Riwanto3
1Diponegoro University, Faculty of Medicine, Department of Surgery, Paediatric Surgery, Semarang, Indonesia. aaprasetyo82@gmail.com.
Introduction:
Cholestasis is bile flow disruption that leads to bile accumulation, which could lead to liver fibrosis. Ursodeoxycholic acid (UDCA) has a hepatoprotective effect. Glutathione (GSH) is an endogenous antioxidant that plays a role in maintaining the function and structure of liver cells. This study aimed to examine the effect of UDCA-GSH combination therapy in multiple doses on liver function in the Sprague-Dawley rats' liver fibrosis model.
Materials And Methods:
This was a randomised post-testonly study. A total of 28 rats were assigned into four groups: Group 1 is control group (C), samples had bile duct ligation and UDCA monotherapy 20 mg; Group 2, bile duct ligation + UDCA 10 mg + glutathione 10 mg (P1); Group 3, bile duct ligation + UDCA 20 mg + glutathione 15 mg (P2); Group 4, bile duct ligation + UDCA 30 mg + glutathione 20 mg (P3). Serum AST, ALT, ALP activity, total, direct and indirect bilirubin were collected. Shapiro-Wilk test was used for the normality test. All groups' data were compared using Kruskall-Wallis and Mann-Whitney tests.
Results:
There was a significant difference in the ALP level in all rats and between the C and P2 groups. ALP level of all groups decreased significantly compared to the control group. Combination therapy group showed lower bilirubin levels. ALT levels significantly differed between the C-P1, P1-P2, and P1-P3 groups.
Conclusion:
UDCA-GSH therapy improves liver function in BDL rats' models compared to UDCA monotherapy.
